CHARLES RIVER LABORATORIES (CRL) Stock Fundamental Analysis
NYSE:CRL - New York Stock Exchange, Inc. - US1598641074 - Common Stock - Currency: USD
Taking everything into account, CRL scores 4 out of 10 in our fundamental rating. CRL was compared to 56 industry peers in the Life Sciences Tools & Services industry. CRL has an average financial health and profitability rating. CRL has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year CRL was profitable.
In the past year CRL had a positive cash flow from operations.
In the past 5 years CRL has always been profitable.
CRL had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
CRL has a better Return On Assets (-0.42%) than 67.86% of its industry peers.
CRL's Return On Equity of -0.99% is fine compared to the rest of the industry. CRL outperforms 69.64% of its industry peers.
CRL's Return On Invested Capital of 6.12% is fine compared to the rest of the industry. CRL outperforms 73.21% of its industry peers.
The Average Return On Invested Capital over the past 3 years for CRL is significantly below the industry average of 12.97%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.42% | ||
| ROE | -0.99% | ||
| ROIC | 6.12% |
ROA(3y)4.11%
ROA(5y)4.9%
ROE(3y)9.94%
ROE(5y)12.5%
ROIC(3y)7.32%
ROIC(5y)7.6%
1.3 Margins
CRL's Profit Margin has declined in the last couple of years.
CRL's Operating Margin of 12.59% is fine compared to the rest of the industry. CRL outperforms 73.21% of its industry peers.
CRL's Operating Margin has been stable in the last couple of years.
Looking at the Gross Margin, with a value of 34.69%, CRL is doing worse than 64.29% of the companies in the same industry.
In the last couple of years the Gross Margin of CRL has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.59% | ||
| PM (TTM) | N/A | ||
| GM | 34.69% |
OM growth 3Y-8.72%
OM growth 5Y-1.4%
PM growth 3Y-71.55%
PM growth 5Y-51.64%
GM growth 3Y-2.67%
GM growth 5Y-1%
2. Health
2.1 Basic Checks
CRL has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for CRL has been reduced compared to 1 year ago.
The number of shares outstanding for CRL has been increased compared to 5 years ago.
The debt/assets ratio for CRL has been reduced compared to a year ago.
2.2 Solvency
CRL has an Altman-Z score of 2.13. This is not the best score and indicates that CRL is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.13, CRL is in line with its industry, outperforming 58.93% of the companies in the same industry.
The Debt to FCF ratio of CRL is 4.46, which is a neutral value as it means it would take CRL, 4.46 years of fcf income to pay off all of its debts.
CRL has a Debt to FCF ratio of 4.46. This is in the better half of the industry: CRL outperforms 71.43% of its industry peers.
A Debt/Equity ratio of 0.79 indicates that CRL is somewhat dependend on debt financing.
The Debt to Equity ratio of CRL (0.79) is worse than 76.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.79 | ||
| Debt/FCF | 4.46 | ||
| Altman-Z | 2.13 |
ROIC/WACC0.61
WACC10.07%
2.3 Liquidity
A Current Ratio of 1.43 indicates that CRL should not have too much problems paying its short term obligations.
CRL has a worse Current ratio (1.43) than 76.79% of its industry peers.
A Quick Ratio of 1.16 indicates that CRL should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.16, CRL is doing worse than 75.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.43 | ||
| Quick Ratio | 1.16 |
3. Growth
3.1 Past
CRL shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.47%.
CRL shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 8.93% yearly.
Looking at the last year, CRL shows a decrease in Revenue. The Revenue has decreased by -2.16% in the last year.
CRL shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.09% yearly.
EPS 1Y (TTM)2.47%
EPS 3Y-0.03%
EPS 5Y8.93%
EPS Q2Q%3.08%
Revenue 1Y (TTM)-2.16%
Revenue growth 3Y4.59%
Revenue growth 5Y9.09%
Sales Q2Q%-2.71%
3.2 Future
The Earnings Per Share is expected to grow by 5.70% on average over the next years.
CRL is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.74% yearly.
EPS Next Y-6.16%
EPS Next 2Y0.04%
EPS Next 3Y2.95%
EPS Next 5Y5.7%
Revenue Next Year-3.49%
Revenue Next 2Y-0.58%
Revenue Next 3Y1.34%
Revenue Next 5Y3.74%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 13.26, the valuation of CRL can be described as correct.
Based on the Price/Earnings ratio, CRL is valued cheaper than 89.29% of the companies in the same industry.
CRL's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.60.
A Price/Forward Earnings ratio of 13.34 indicates a correct valuation of CRL.
89.29% of the companies in the same industry are more expensive than CRL, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of CRL to the average of the S&P500 Index (22.43), we can say CRL is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.26 | ||
| Fwd PE | 13.34 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CRL is valued cheaper than 96.43% of the companies in the same industry.
94.64% of the companies in the same industry are more expensive than CRL, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.01 | ||
| EV/EBITDA | 10.34 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)1.49
EPS Next 2Y0.04%
EPS Next 3Y2.95%
5. Dividend
5.1 Amount
No dividends for CRL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSE:CRL (5/21/2025, 12:54:09 PM)
137.74
-5.79 (-4.03%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners105.79%
Inst Owner Change0.68%
Ins Owners0.83%
Ins Owner Change2.52%
Market Cap6.77B
Analysts63.33
Price Target150.62 (9.35%)
Short Float %5.43%
Short Ratio1.45
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.73%
Min EPS beat(2)4.03%
Max EPS beat(2)11.44%
EPS beat(4)4
Avg EPS beat(4)9.24%
Min EPS beat(4)4.03%
Max EPS beat(4)15.8%
EPS beat(8)8
Avg EPS beat(8)7.7%
EPS beat(12)12
Avg EPS beat(12)6.68%
EPS beat(16)16
Avg EPS beat(16)5.87%
Revenue beat(2)2
Avg Revenue beat(2)2.18%
Min Revenue beat(2)0.91%
Max Revenue beat(2)3.45%
Revenue beat(4)3
Avg Revenue beat(4)1.48%
Min Revenue beat(4)-0.86%
Max Revenue beat(4)3.45%
Revenue beat(8)6
Avg Revenue beat(8)1.16%
Revenue beat(12)9
Avg Revenue beat(12)1.3%
Revenue beat(16)11
Avg Revenue beat(16)1.06%
PT rev (1m)-16.57%
PT rev (3m)-24.75%
EPS NQ rev (1m)5.49%
EPS NQ rev (3m)4.72%
EPS NY rev (1m)2.79%
EPS NY rev (3m)-1.39%
Revenue NQ rev (1m)2.65%
Revenue NQ rev (3m)1.23%
Revenue NY rev (1m)1.84%
Revenue NY rev (3m)-1.58%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.26 | ||
| Fwd PE | 13.34 | ||
| P/S | 1.68 | ||
| P/FCF | 12.01 | ||
| P/OCF | 8.71 | ||
| P/B | 2.12 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.34 |
EPS(TTM)10.39
EY7.54%
EPS(NY)10.33
Fwd EY7.5%
FCF(TTM)11.47
FCFY8.32%
OCF(TTM)15.81
OCFY11.48%
SpS81.89
BVpS65.03
TBVpS-6.82
PEG (NY)N/A
PEG (5Y)1.49
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.42% | ||
| ROE | -0.99% | ||
| ROCE | 7.75% | ||
| ROIC | 6.12% | ||
| ROICexc | 6.35% | ||
| ROICexgc | 14.43% | ||
| OM | 12.59% | ||
| PM (TTM) | N/A | ||
| GM | 34.69% | ||
| FCFM | 14% |
ROA(3y)4.11%
ROA(5y)4.9%
ROE(3y)9.94%
ROE(5y)12.5%
ROIC(3y)7.32%
ROIC(5y)7.6%
ROICexc(3y)7.59%
ROICexc(5y)7.91%
ROICexgc(3y)18.25%
ROICexgc(5y)19.94%
ROCE(3y)9.27%
ROCE(5y)9.62%
ROICexcg growth 3Y-14.69%
ROICexcg growth 5Y-4.68%
ROICexc growth 3Y-7.59%
ROICexc growth 5Y-3.19%
OM growth 3Y-8.72%
OM growth 5Y-1.4%
PM growth 3Y-71.55%
PM growth 5Y-51.64%
GM growth 3Y-2.67%
GM growth 5Y-1%
F-Score4
Asset Turnover0.53
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.79 | ||
| Debt/FCF | 4.46 | ||
| Debt/EBITDA | 2.78 | ||
| Cap/Depr | 53.72% | ||
| Cap/Sales | 5.3% | ||
| Interest Coverage | 4.43 | ||
| Cash Conversion | 85.97% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.43 | ||
| Quick Ratio | 1.16 | ||
| Altman-Z | 2.13 |
F-Score4
WACC10.07%
ROIC/WACC0.61
Cap/Depr(3y)90.89%
Cap/Depr(5y)85.95%
Cap/Sales(3y)7.21%
Cap/Sales(5y)6.76%
Profit Quality(3y)1669.68%
Profit Quality(5y)1049.89%
High Growth Momentum
Growth
EPS 1Y (TTM)2.47%
EPS 3Y-0.03%
EPS 5Y8.93%
EPS Q2Q%3.08%
EPS Next Y-6.16%
EPS Next 2Y0.04%
EPS Next 3Y2.95%
EPS Next 5Y5.7%
Revenue 1Y (TTM)-2.16%
Revenue growth 3Y4.59%
Revenue growth 5Y9.09%
Sales Q2Q%-2.71%
Revenue Next Year-3.49%
Revenue Next 2Y-0.58%
Revenue Next 3Y1.34%
Revenue Next 5Y3.74%
EBIT growth 1Y-19.26%
EBIT growth 3Y-4.53%
EBIT growth 5Y7.56%
EBIT Next Year27.88%
EBIT Next 3Y14.43%
EBIT Next 5Y11.83%
FCF growth 1Y104.63%
FCF growth 3Y-1.94%
FCF growth 5Y8.06%
OCF growth 1Y23.95%
OCF growth 3Y-1.16%
OCF growth 5Y8.84%